文献速递呼吸衰竭与机械通气心脑血管急症

YEARS 算法用于癌症患者疑似肺栓塞的诊断:一项随机临床试验

YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01
一句话结论在活动性癌症疑似急性肺栓塞患者中,YEARS 诊断算法与直接 CTPA 策略同样安全,且可使 22% 的患者免于 CTPA。

Hydra 研究为开放标签、随机、非劣效性试验,纳入 21 家医院急诊或内科病房的 698 例活动性癌症疑似急性肺栓塞患者,1:1 随机接受 YEARS 算法(评估 YEARS 条目、D-二聚体、风险依赖性 CTPA)或直接 CTPA。符合方案分析中,排除肺栓塞后 90 天内症状性静脉血栓栓塞或(可能)肺栓塞相关死亡在 YEARS 组为 1.8%(5/282),CTPA 组为 5.5%(15/273),绝对风险差 -3.7%(99.9%CI -8.8% 至 1.4%),非劣效性成立。YEARS 组 22%(77/352)的患者未行 CTPA 即完成诊断管理,两组阴性 CTPA 比例无差异。

要点

  • 活动性癌症疑似急性肺栓塞患者,YEARS 算法排除肺栓塞后 90 天血栓栓塞事件率 1.8%,非劣于直接 CTPA 策略的 5.5%。
  • YEARS 算法组 22%(77/352)的患者未接受 CTPA 即完成诊断管理,避免了 CT 肺动脉造影。
  • 符合方案分析绝对风险差 -3.7%(99.9%CI -8.8% 至 1.4%),非劣效性界值上限 2.6%,P=3.4×10⁻⁵。
  • 意向诊断分析绝对风险差 -2.6%(99.9%CI -7.5% 至 2.4%),非劣效性 P=5.9×10⁻⁴。

适用人群与场景

  • 活动性癌症且疑似急性肺栓塞的成人患者,来自荷兰、意大利、瑞士、比利时、法国、西班牙 21 家医院的急诊科或内科病房。
  • 中位年龄 65 岁(IQR 56-72 岁),女性 422 例(60%),共 698 例随机。

诊断标准与关键阈值

  • YEARS 算法组成:评估 YEARS 条目、D-二聚体水平,并执行风险依赖性 CTPA;原文未给出 YEARS 条目具体内容及 D-二聚体阈值。
  • 非劣效性界值:主要终点绝对风险差单侧 99.9%CI 上限 2.6%。

处置流程与药物剂量

  • 第一步:对活动性癌症疑似急性肺栓塞患者随机采用 YEARS 算法或直接 CTPA 策略。
  • 第二步:YEARS 算法组评估 YEARS 条目和 D-二聚体,按风险决定是否行 CTPA;原文未给出具体药物剂量、给药途径或频次。
  • 第三步:若按 YEARS 算法排除肺栓塞,则不做 CTPA,该组 22%(77/352)患者未行 CTPA。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:开放标签、随机、研究者发起、非劣效性试验,盲法中心结局裁定,2019 年 8 月 22 日至 2025 年 8 月 21 日随访。
  • 样本量与中心:698 例随机(YEARS 组 n=352,CTPA 组 n=346),21 家医院,来自 6 个国家。
  • 人群:活动性癌症疑似急性肺栓塞,中位年龄 65 岁,女性 60%,104 例(15%)基线诊断肺栓塞,1 例失访。
  • 干预与对照:YEARS 算法(评估 YEARS 条目、D-二聚体、风险依赖性 CTPA)vs 直接 CTPA。
  • 主要终点:符合方案分析中,排除肺栓塞后 90 天内症状性静脉血栓栓塞或(可能)肺栓塞相关死亡,YEARS 组 5/282(1.8%)vs CTPA 组 15/273(5.5%),绝对风险差 -3.7%(99.9%CI -8.8% 至 1.4%),非劣效性 P=3.4×10⁻⁵。
  • 意向诊断分析:绝对风险差 -2.6%(99.9%CI -7.5% 至 2.4%),非劣效性 P=5.9×10⁻⁴。
  • 其他:YEARS 组 77/352(22%)未行 CTPA 即完成诊断管理;原文未报告不良事件细节。

证据类型、等级与局限

  • 证据类型:随机对照非劣效性试验(RCT),开放标签,盲法中心结局裁定。
  • 证据等级或推荐强度:原文未提及正式证据分级。
  • 局限:开放标签设计;原文未提及样本量计算细节;随访至 2025 年 8 月 21 日;结果基于符合方案和意向诊断分析;原文未报告不良事件。

对床旁实践的改变

  • 在活动性癌症疑似急性肺栓塞患者中,可考虑采用 YEARS 算法替代直接 CTPA 策略,以避免约 22% 的 CTPA。
  • 该策略在原文人群中非劣于直接 CTPA,但原文未提供 YEARS 条目具体内容和 D-二聚体阈值,床旁实施需参照原始算法定义。

指南或共识出处

  • 原文未提及指南或共识名称;试验注册号 ccmo.nl Identifier: NL-OMON52383。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Although the YEARS algorithm is a safe and efficient way to rule out acute pulmonary embolism (PE), robust evidence on its accuracy in patients with cancer is lacking, and current guidelines suggest proceeding directly to computed tomographic pulmonary angiography (CTPA).

OBJECTIVE: To compare the safety and efficiency of the YEARS algorithm with CTPA only to rule out acute PE in patients with active cancer.

DESIGN, SETTING, AND PARTICIPANTS: The Hydra study was an open-label, randomized, investigator-initiated, noninferiority trial with blinded central outcome adjudication conducted from August 22, 2019, to August 21, 2025, the date of final follow-up. Patients with active cancer and suspected acute PE were recruited from emergency departments or medical units in 21 hospitals in the Netherlands, Italy, Switzerland, Belgium, France, and Spain.

INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive diagnostic management by the YEARS algorithm (n = 352)-consisting of assessing YEARS items, D-dimer levels, and performing risk-dependent CTPA-or by CTPA only (n = 346).

MAIN OUTCOMES AND MEASURES: The primary outcome was centrally adjudicated symptomatic venous thromboembolism or (possible) PE-related death within 90 days after ruling out PE at baseline, assessed in a per-protocol noninferiority analysis with a 2.6% margin for the upper bound of a 1-sided 99.9% CI. The key secondary outcome was the proportion of negative CTPA results at baseline, assessed in a superiority analysis.

RESULTS: A total of 698 patients were randomized (median age, 65 years [IQR, 56-72 years], 422 female [60%]), and 104 patients (15%) had PE diagnosed at baseline. One patient was lost to follow-up. Of those in whom PE was considered excluded, 5 of 282 patients (1.8%) in the per-protocol YEARS group vs 15 of 273 patients (5.5%) in the per-protocol CTPA-only group had a primary outcome (absolute risk difference, -3.7%; 99.9% CI, -8.8% to 1.4%; P = 3.4 × 10-5 for noninferiority). In the intention-to-diagnosis analysis, the absolute risk difference between the YEARS algorithm and CTPA only was -2.6% (99.9% CI, -7.5% to 2.4%; P = 5.9 × 10-4 for noninferiority). Diagnostic management of PE was carried out for 77 of 352 patients (22%) in the YEARS group without CTPA. No difference in the proportion of negative CTPA (P = .93) was observed between the groups.

CONCLUSIONS AND RELEVANCE: In patients with cancer and suspected PE, a diagnostic strategy using the YEARS diagnostic algorithm was as safe as using CTPA only, thus, obviating the need to perform CTPA in 22% of patients.

TRIAL REGISTRATION: ccmo.nl Identifier: NL-OMON52383.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Akerboom B, Martens ESL, Stals MAM, et al. YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2026. PMID: 42437322. doi:10.1001/jama.2026.10676

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。